Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia
Identifieur interne : 003935 ( Main/Exploration ); précédent : 003934; suivant : 003936Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia
Auteurs : Stewart A. Factor [États-Unis] ; Eric S. Molho [États-Unis] ; Sharon Evans [États-Unis] ; Paul J. Feustel [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-09.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Bontoxilysin, Botulinum Toxins, Type A (administration & dosage), Botulinum Toxins, Type A (adverse effects), Botulinum Toxins, Type A (therapeutic use), Dystonia, Electromyography, Female, Humans, Injections, Intramuscular, Male, Middle Aged, Nervous system diseases, Neuromuscular Agents (administration & dosage), Neuromuscular Agents (adverse effects), Neuromuscular Agents (therapeutic use), Prospective Studies, Questionnaires, Safety, Torticollis (diagnosis), Torticollis (drug therapy), Torticollis (physiopathology), botulinum toxin type A, botulinum toxin type B, cervical dystonia, secondary non‐response.
- MESH :
- chemical , administration & dosage : Botulinum Toxins, Type A, Neuromuscular Agents.
- chemical , adverse effects : Botulinum Toxins, Type A, Neuromuscular Agents.
- chemical , therapeutic use : Botulinum Toxins, Type A, Neuromuscular Agents.
- diagnosis : Torticollis.
- drug therapy : Torticollis.
- physiopathology : Torticollis.
- Electromyography, Female, Humans, Injections, Intramuscular, Male, Middle Aged, Prospective Studies, Questionnaires.
Abstract
Efficacy of botulinum toxin type B (BoNT B) for the treatment of type A‐resistant (AR) and non‐A‐resistant (NAR) cervical dystonia (CD) has been demonstrated in several single injection studies. There is little data available on long‐term therapy with repeated injection sessions and it is unknown if AR and NAR patients respond in a similar manner over time. To evaluate the long‐term efficacy and safety of BoNT B in AR and NAR CD patients, we carried out a prospective, open‐label study examining 10 repeated dosing sessions of BoNT B in 34 patients with CD (15 AR and 19 NAR). Dosing was started at 10,000 units and could be increased to 25,000. Assessments included the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) and a patient global assessment at each baseline (injection) and Week 4 (peak effect) visit. Change in TWSTRS total was the primary efficacy end point. Data was analyzed using repeated‐measures analysis of variance. BoNT B therapy resulted in an overall significant improvement of CD (P < 0.001) and improvement was seen in all 10 individual sessions (2.5 years). The magnitude of response decayed over time (P < 0.001). There was no difference between AR and NAR patients with regard to dose, treatment effect, or decay in response. The AR group perceived (patient global) treatment as being less effective (P = 0.047). Dry mouth frequency decreased with each session despite increasing doses whereas flu‐like syndrome and weakness increased. BoNT B therapy provides long‐term benefit for CD patients but the magnitude of response diminishes over time. The cause of this decay is probably multifactorial. AR and NAR CD patients respond in a similar fashion. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20531
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000111
- to stream Istex, to step Curation: 000111
- to stream Istex, to step Checkpoint: 002345
- to stream PubMed, to step Corpus: 003025
- to stream PubMed, to step Curation: 003025
- to stream PubMed, to step Checkpoint: 003147
- to stream Ncbi, to step Merge: 001287
- to stream Ncbi, to step Curation: 001287
- to stream Ncbi, to step Checkpoint: 001287
- to stream Main, to step Merge: 005022
- to stream PascalFrancis, to step Corpus: 001D47
- to stream PascalFrancis, to step Curation: 000F74
- to stream PascalFrancis, to step Checkpoint: 001E61
- to stream Main, to step Merge: 005339
- to stream Main, to step Curation: 003935
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia</title><author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name></author><author><name sortKey="Molho, Eric S" sort="Molho, Eric S" uniqKey="Molho E" first="Eric S." last="Molho">Eric S. Molho</name></author><author><name sortKey="Evans, Sharon" sort="Evans, Sharon" uniqKey="Evans S" first="Sharon" last="Evans">Sharon Evans</name></author><author><name sortKey="Feustel, Paul J" sort="Feustel, Paul J" uniqKey="Feustel P" first="Paul J." last="Feustel">Paul J. Feustel</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F9947FDDED9AC82D2AD35D1B5D093A31B53597A8</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20531</idno><idno type="url">https://api.istex.fr/document/F9947FDDED9AC82D2AD35D1B5D093A31B53597A8/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000111</idno><idno type="wicri:Area/Istex/Curation">000111</idno><idno type="wicri:Area/Istex/Checkpoint">002345</idno><idno type="wicri:doubleKey">0885-3185:2005:Factor S:efficacy:and:safety</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15954134</idno><idno type="wicri:Area/PubMed/Corpus">003025</idno><idno type="wicri:Area/PubMed/Curation">003025</idno><idno type="wicri:Area/PubMed/Checkpoint">003147</idno><idno type="wicri:Area/Ncbi/Merge">001287</idno><idno type="wicri:Area/Ncbi/Curation">001287</idno><idno type="wicri:Area/Ncbi/Checkpoint">001287</idno><idno type="wicri:doubleKey">0885-3185:2005:Factor S:efficacy:and:safety</idno><idno type="wicri:Area/Main/Merge">005022</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:05-0493089</idno><idno type="wicri:Area/PascalFrancis/Corpus">001D47</idno><idno type="wicri:Area/PascalFrancis/Curation">000F74</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001E61</idno><idno type="wicri:doubleKey">0885-3185:2005:Factor S:efficacy:and:safety</idno><idno type="wicri:Area/Main/Merge">005339</idno><idno type="wicri:Area/Main/Curation">003935</idno><idno type="wicri:Area/Main/Exploration">003935</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia</title><author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center of Albany Medical Center, Albany, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Emory University, Atlanta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Molho, Eric S" sort="Molho, Eric S" uniqKey="Molho E" first="Eric S." last="Molho">Eric S. Molho</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center of Albany Medical Center, Albany, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Evans, Sharon" sort="Evans, Sharon" uniqKey="Evans S" first="Sharon" last="Evans">Sharon Evans</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center of Albany Medical Center, Albany, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Feustel, Paul J" sort="Feustel, Paul J" uniqKey="Feustel P" first="Paul J." last="Feustel">Paul J. Feustel</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Neuropharmacology and Neuroscience, Albany Medical Center, Albany, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-09">2005-09</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1152">1152</biblScope><biblScope unit="page" to="1160">1160</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">F9947FDDED9AC82D2AD35D1B5D093A31B53597A8</idno><idno type="DOI">10.1002/mds.20531</idno><idno type="ArticleID">MDS20531</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bontoxilysin</term><term>Botulinum Toxins, Type A (administration & dosage)</term><term>Botulinum Toxins, Type A (adverse effects)</term><term>Botulinum Toxins, Type A (therapeutic use)</term><term>Dystonia</term><term>Electromyography</term><term>Female</term><term>Humans</term><term>Injections, Intramuscular</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Neuromuscular Agents (administration & dosage)</term><term>Neuromuscular Agents (adverse effects)</term><term>Neuromuscular Agents (therapeutic use)</term><term>Prospective Studies</term><term>Questionnaires</term><term>Safety</term><term>Torticollis (diagnosis)</term><term>Torticollis (drug therapy)</term><term>Torticollis (physiopathology)</term><term>botulinum toxin type A</term><term>botulinum toxin type B</term><term>cervical dystonia</term><term>secondary non‐response</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Botulinum Toxins, Type A</term><term>Neuromuscular Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Botulinum Toxins, Type A</term><term>Neuromuscular Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term><term>Neuromuscular Agents</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Torticollis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Torticollis</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Torticollis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Electromyography</term><term>Female</term><term>Humans</term><term>Injections, Intramuscular</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Questionnaires</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Bontoxilysin</term><term>Dystonie</term><term>Système nerveux pathologie</term><term>Sécurité</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Efficacy of botulinum toxin type B (BoNT B) for the treatment of type A‐resistant (AR) and non‐A‐resistant (NAR) cervical dystonia (CD) has been demonstrated in several single injection studies. There is little data available on long‐term therapy with repeated injection sessions and it is unknown if AR and NAR patients respond in a similar manner over time. To evaluate the long‐term efficacy and safety of BoNT B in AR and NAR CD patients, we carried out a prospective, open‐label study examining 10 repeated dosing sessions of BoNT B in 34 patients with CD (15 AR and 19 NAR). Dosing was started at 10,000 units and could be increased to 25,000. Assessments included the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) and a patient global assessment at each baseline (injection) and Week 4 (peak effect) visit. Change in TWSTRS total was the primary efficacy end point. Data was analyzed using repeated‐measures analysis of variance. BoNT B therapy resulted in an overall significant improvement of CD (P < 0.001) and improvement was seen in all 10 individual sessions (2.5 years). The magnitude of response decayed over time (P < 0.001). There was no difference between AR and NAR patients with regard to dose, treatment effect, or decay in response. The AR group perceived (patient global) treatment as being less effective (P = 0.047). Dry mouth frequency decreased with each session despite increasing doses whereas flu‐like syndrome and weakness increased. BoNT B therapy provides long‐term benefit for CD patients but the magnitude of response diminishes over time. The cause of this decay is probably multifactorial. AR and NAR CD patients respond in a similar fashion. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Géorgie (États-Unis)</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name></region><name sortKey="Evans, Sharon" sort="Evans, Sharon" uniqKey="Evans S" first="Sharon" last="Evans">Sharon Evans</name><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name><name sortKey="Feustel, Paul J" sort="Feustel, Paul J" uniqKey="Feustel P" first="Paul J." last="Feustel">Paul J. Feustel</name><name sortKey="Molho, Eric S" sort="Molho, Eric S" uniqKey="Molho E" first="Eric S." last="Molho">Eric S. Molho</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003935 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003935 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F9947FDDED9AC82D2AD35D1B5D093A31B53597A8
|texte= Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia
}}
| This area was generated with Dilib version V0.6.23. |  |